MicroRNA-15a promotes prostate cancer cell ferroptosis by inhibiting GPX4 expression

Po Xu1, Ying Wang2, Zhe Deng1

  • 1Department of Emergency, The First Affiliated Hospital, Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518000, P.R. China.

Oncology Letters
|January 24, 2022
PubMed

Insights

MicroRNA-15a induces ferroptosis in prostate cancer cells by targeting glutathione peroxidase 4 (GPX4). This finding offers new therapeutic strategies for prostate cancer treatment by regulating cell death pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Ferroptosis is a regulated cell death form marked by lipid reactive oxygen species (ROS) accumulation and glutathione peroxidase 4 (GPX4) inactivation.
  • Prostate cancer remains a significant health concern, necessitating novel therapeutic targets and strategies.

Purpose of the Study:

  • To investigate the role of microRNA (miR)-15a in ferroptosis of prostate cancer cells.
  • To elucidate the regulatory mechanism of miR-15a on GPX4 expression in prostate cancer.

Main Methods:

  • Bioinformatics analysis to predict miR-15a and GPX4 mRNA interaction.
  • Transfection of prostate cancer cells (LNCAP) with miR-15a mimics or si-GPX4.
  • Quantitative PCR, Western blot, RNA pull-down, and dual-luciferase reporter assays to confirm interaction and expression levels.
  • Assays for cell proliferation (CCK-8), LDH release, intracellular iron, ROS, mitochondrial membrane potential (MMP), and lipid peroxidation (MDA).

Main Results:

  • miR-15a mimics transfection decreased GPX4 protein expression.
  • miR-15a directly targets the 3'-UTR of GPX4 mRNA.
  • Both miR-15a mimics and si-GPX4 suppressed cell proliferation, increased LDH release, and elevated intracellular iron, ROS, and MDA levels.
  • Disruption of MMP was observed in both treatment groups.

Conclusions:

  • miR-15a induces ferroptosis in prostate cancer cells by downregulating GPX4.
  • This regulatory axis presents a potential therapeutic target for prostate cancer treatment.